single asset biotech risk
Capricor Buys More Time on Deramiocel as an Investor Pushes for Board Change
Capricor’s FDA deadline came and went last Saturday with no announcement. Two days later, the company said the agency had granted a three-month extension instead of a decision. The same week, an activist investor sent Capricor’s other shareholders a letter demanding a board shake-up, timed to land in the middle of the company’s most consequential…
Tenax Therapeutics Stock Craters 90% After Phase 3 Trial Misses Primary Endpoint
Tenax Therapeutics closed at $13.45 on Friday. It opened Monday at $1.77. In between, the company’s only Phase 3 trial reported a treatment difference of 3.5 meters on its primary endpoint, a result so far from significance that seven Wall Street analysts cut their price targets by roughly 90% apiece within a single trading day.…
